DATE: April 25, 2017
TIME: 10:00am PT, 1:00pm ET

Immunotherapy has emerged as one of the most promising options for the future treatment of a growing number of cancers and is touted to be the next revolution in our fight against this complex disease. One of the most effective modalities of treatment, thus far, has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors.

Current biomarkers and immunohistochemistry (IHC) assays are not accurate predictors of which individuals are most likely to respond or benefit from immunotherapeutic agents, thus prompting the need to identify better biomarkers that can guide therapy selection in the future. 

Next-generation sequencing (NGS) offers clinical researchers a cost-efficient and rapid way of analyzing multiple targets simultaneously from as little as 10ng of total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.  

In this webinar, our speakers will show how Thermo Fisher Scientific’s Oncomine Immune Response Research Assay enables the interrogation of gene targets that are critical for research into immune response.
 
Topics to be covered:

• Fiona Hyland will describe how the content for a new gene expression NGS-based assay was carefully selected and will compare its performance against other assay(s) available on the market.
• Dr. Carl Morrison will describe a verification study for establishing the performance of the new Oncomine Immune Response Research Assay in a clinical research lab.

Key learning objectives for attendees:

• How to improve immuno-oncology biomarker discovery using NGS
• Benefits of applying a targeted gene-expression based approach for studying the tumor microenvironment
• How to implement the Oncomine Immune Response Research Assay in a clinical research lab 

Who should attend:

• Scientists involved in biomarker discovery and drug development 
• Contract Research Organizations focused on oncology services
• Immunology and oncology translational/clinical research laboratories interested in adopting NGS

For Research Use Only. Not for use in diagnostic procedures.